Empagliflozin in the treatment of type 2 diabetes: evidence to date
نویسندگان
چکیده
In the last decade, researchers have gained a greater understanding of the pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of the more recent treatment targets is the kidney. The kidneys become maladaptive in diabetes by increasing the reabsorption of glucose above the normal physiologic renal threshold. This discovery has led to the development of the sodium/glucose cotransporter 2 inhibitors (SGLT2). These agents readjust the renal threshold for glucose reabsorption to a lower level and decrease glucose reabsorption, while increasing urinary glucose when the glucose is above the renal threshold and subsequently lowering plasma glucose. The mechanism of action of the SGLT2 inhibitors is insulin independent, which makes them a novel treatment of diabetes. At the time of preparation of this manuscript, there were three SGLT2 inhibitors available in the US. This manuscript focuses on empagliflozin, the newest SGLT2 inhibitor, the trials in its development, and the clinical data available to date. Further, the authors propose future applications of empagliflozin, including in the treatment of type 1 diabetes, and its potential role in renoprotection.
منابع مشابه
Effects of Empagliflozin on Sexual Function, Testicular Histology and Biochemical Parameters in Young and Middle-Aged Diabetic Rats of Type2
Background: Empagliflozin, selective glucose-sodium inhibitor of the latest drugs in the treatment of type 2 diabetes. Diabetes induced hypogonadism disrupts sexual function. There is a direct relationship between reducing blood glucose and reduced libido. In this project, the anti-diabetic drug Empagliflozin in addition to treatment has been studied, in terms of effect on sexual function. Met...
متن کاملEvaluation of the Effect of Empagliflozin Therapy on T Helper 22 Cell-Related Factors in Patients with Type 2 Diabetes Mellitus
Background and Objective:The increased response of T helper (Th) 22cells might be involved in thepathogenesis ofType 2 Diabetes Mellitus (T2DM). The present study aimed to investigate the transcription factor of Th22 cells (aryl hydrocarbon receptor [AHR]) and interleukin 22 (IL-22) in CD4+ T cells as well as the impact of oral empagliflozin treatment. The correlation between the aforementioned...
متن کاملEffect of Empagliflozin on Electrolytes and Lipid Profiles in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Introduction: Studies examining the effect of Empagliflozin in patients with type 2 diabetes have reported different results regarding the effect of this drug on electrolytes and lipid profiles. This study aimed to evaluate the effect of Empagliflozin on electrolytes and lipid profiles in patients with type 2 diabetes. Materials and Methods: In this systematic meta-analysis, clinical trials pub...
متن کاملOptions for empagliflozin in combination therapy in type 2 diabetes mellitus
OBJECTIVE To update clinicians with an overview of empagliflozin for the treatment of type 2 diabetes mellitus (T2DM), with focus on use in combination regimens. METHODS Keyword searches were conducted in the Medline database to identify literature reporting clinical trials of at least 12 weeks' duration using empagliflozin treatment in patients with T2DM. RESULTS When given as monotherapy ...
متن کاملEmpagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
BACKGROUND The availability of a dual sodium glucose co-transporter 2/dipeptidyl peptidase-4 inhibitor combination in a single-tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). AIM The aim of this st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 9 شماره
صفحات -
تاریخ انتشار 2015